Ayobami Akenroye, M.B.,Ch.B.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Asthmatic Agents | 16 | 2024 | 571 | 8.540 |
Why?
|
| Asthma | 26 | 2024 | 6195 | 5.230 |
Why?
|
| Biological Products | 10 | 2024 | 911 | 4.160 |
Why?
|
| Pulmonary Eosinophilia | 2 | 2022 | 78 | 1.590 |
Why?
|
| Eosinophils | 4 | 2024 | 947 | 1.430 |
Why?
|
| Immunoglobulin E | 5 | 2024 | 1494 | 1.350 |
Why?
|
| Chemokine CCL17 | 1 | 2024 | 26 | 0.940 |
Why?
|
| Chemokine CXCL10 | 1 | 2024 | 316 | 0.840 |
Why?
|
| Interleukin-13 | 1 | 2024 | 375 | 0.790 |
Why?
|
| Hypersensitivity | 4 | 2023 | 1157 | 0.780 |
Why?
|
| Respiratory Sounds | 1 | 2023 | 701 | 0.650 |
Why?
|
| Respiratory Function Tests | 1 | 2024 | 1681 | 0.640 |
Why?
|
| Coronavirus | 1 | 2020 | 153 | 0.600 |
Why?
|
| Efficiency | 1 | 2021 | 476 | 0.590 |
Why?
|
| TNF Receptor-Associated Factor 5 | 1 | 2017 | 6 | 0.580 |
Why?
|
| TYK2 Kinase | 1 | 2017 | 38 | 0.570 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2020 | 1874 | 0.560 |
Why?
|
| Urticaria | 1 | 2018 | 150 | 0.550 |
Why?
|
| Acetates | 1 | 2018 | 321 | 0.550 |
Why?
|
| Angioedema | 1 | 2018 | 192 | 0.540 |
Why?
|
| Hospitals, Pediatric | 3 | 2014 | 1859 | 0.530 |
Why?
|
| Urban Population | 1 | 2024 | 2032 | 0.520 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2017 | 262 | 0.520 |
Why?
|
| Eligibility Determination | 1 | 2019 | 420 | 0.520 |
Why?
|
| Reminder Systems | 1 | 2017 | 387 | 0.450 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2017 | 269 | 0.420 |
Why?
|
| Quinolines | 1 | 2018 | 764 | 0.410 |
Why?
|
| Medicine | 1 | 2021 | 941 | 0.410 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3080 | 0.410 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3200 | 0.410 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 1117 | 0.400 |
Why?
|
| Emergency Service, Hospital | 4 | 2015 | 7860 | 0.390 |
Why?
|
| Anaphylaxis | 1 | 2018 | 757 | 0.370 |
Why?
|
| Spain | 2 | 2023 | 489 | 0.360 |
Why?
|
| Air Pollution | 1 | 2024 | 2342 | 0.350 |
Why?
|
| Antibodies, Monoclonal | 3 | 2023 | 9176 | 0.320 |
Why?
|
| Humans | 41 | 2024 | 760437 | 0.300 |
Why?
|
| Hospital Costs | 1 | 2013 | 948 | 0.290 |
Why?
|
| Health Resources | 1 | 2013 | 935 | 0.290 |
Why?
|
| Bronchiolitis | 1 | 2013 | 485 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 7380 | 0.280 |
Why?
|
| Hospitalization | 3 | 2024 | 10698 | 0.280 |
Why?
|
| Genotype | 1 | 2021 | 12976 | 0.270 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 3701 | 0.260 |
Why?
|
| Lung | 2 | 2024 | 9973 | 0.260 |
Why?
|
| Treatment Outcome | 8 | 2024 | 64591 | 0.250 |
Why?
|
| New York | 2 | 2018 | 872 | 0.250 |
Why?
|
| Severity of Illness Index | 6 | 2024 | 15820 | 0.250 |
Why?
|
| Quality Improvement | 3 | 2015 | 3798 | 0.250 |
Why?
|
| Intensive Care Units | 1 | 2018 | 3742 | 0.240 |
Why?
|
| Bayes Theorem | 2 | 2022 | 2326 | 0.230 |
Why?
|
| Immunotherapy | 1 | 2019 | 4649 | 0.230 |
Why?
|
| Pandemics | 2 | 2020 | 8623 | 0.220 |
Why?
|
| Myostatin | 1 | 2023 | 128 | 0.210 |
Why?
|
| Child | 9 | 2024 | 80086 | 0.200 |
Why?
|
| Adult | 14 | 2024 | 220781 | 0.200 |
Why?
|
| Mass Screening | 2 | 2017 | 5424 | 0.200 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2017 | 3759 | 0.190 |
Why?
|
| Americas | 1 | 2021 | 111 | 0.190 |
Why?
|
| Male | 17 | 2024 | 360035 | 0.180 |
Why?
|
| HLA-DQ Antigens | 1 | 2021 | 211 | 0.180 |
Why?
|
| Australia | 1 | 2024 | 1245 | 0.180 |
Why?
|
| Female | 17 | 2024 | 391875 | 0.180 |
Why?
|
| Retrospective Studies | 10 | 2024 | 80430 | 0.180 |
Why?
|
| Patient Readmission | 1 | 2014 | 3249 | 0.180 |
Why?
|
| Leukocyte Count | 1 | 2024 | 1596 | 0.170 |
Why?
|
| Pediatrics | 1 | 2015 | 3593 | 0.170 |
Why?
|
| Medical History Taking | 1 | 2023 | 773 | 0.170 |
Why?
|
| Electronic Health Records | 1 | 2017 | 4789 | 0.170 |
Why?
|
| Disease Progression | 3 | 2024 | 13484 | 0.170 |
Why?
|
| Eosinophilia | 1 | 2024 | 560 | 0.160 |
Why?
|
| Interleukin-5 | 1 | 2019 | 269 | 0.160 |
Why?
|
| Mucin-1 | 1 | 2023 | 539 | 0.160 |
Why?
|
| Prevalence | 3 | 2024 | 15698 | 0.150 |
Why?
|
| Peru | 1 | 2021 | 890 | 0.150 |
Why?
|
| Middle Aged | 10 | 2024 | 220382 | 0.150 |
Why?
|
| Nystatin | 1 | 2017 | 22 | 0.150 |
Why?
|
| Models, Organizational | 1 | 2021 | 546 | 0.150 |
Why?
|
| Comparative Effectiveness Research | 1 | 2023 | 708 | 0.150 |
Why?
|
| Emulsifying Agents | 1 | 2017 | 6 | 0.150 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 2017 | 34 | 0.140 |
Why?
|
| Sulfides | 1 | 2018 | 170 | 0.140 |
Why?
|
| Ethylenediamines | 1 | 2017 | 57 | 0.140 |
Why?
|
| Excipients | 1 | 2017 | 98 | 0.140 |
Why?
|
| Dermatitis, Atopic | 1 | 2024 | 716 | 0.140 |
Why?
|
| Bell Palsy | 1 | 2017 | 39 | 0.140 |
Why?
|
| Dermatitis, Contact | 1 | 2017 | 133 | 0.140 |
Why?
|
| Cyclopropanes | 1 | 2018 | 432 | 0.140 |
Why?
|
| Femur Head Necrosis | 1 | 2017 | 132 | 0.130 |
Why?
|
| Rhinitis | 1 | 2024 | 746 | 0.130 |
Why?
|
| Interleukin-4 | 1 | 2019 | 1130 | 0.130 |
Why?
|
| Social Class | 1 | 2024 | 2003 | 0.120 |
Why?
|
| beta-Lactams | 1 | 2016 | 157 | 0.120 |
Why?
|
| Child, Preschool | 4 | 2024 | 42209 | 0.120 |
Why?
|
| Eyelids | 1 | 2017 | 278 | 0.120 |
Why?
|
| Schools | 1 | 2023 | 1488 | 0.120 |
Why?
|
| Incidence | 2 | 2023 | 21322 | 0.120 |
Why?
|
| Guideline Adherence | 2 | 2015 | 2215 | 0.110 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2017 | 173 | 0.110 |
Why?
|
| Metformin | 1 | 2021 | 905 | 0.110 |
Why?
|
| Abscess | 1 | 2017 | 606 | 0.110 |
Why?
|
| Hospitals, Urban | 1 | 2015 | 500 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2024 | 41366 | 0.110 |
Why?
|
| Antibodies, Neutralizing | 1 | 2023 | 1942 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2024 | 4355 | 0.100 |
Why?
|
| Drug Approval | 1 | 2019 | 811 | 0.100 |
Why?
|
| Mutation | 1 | 2017 | 30025 | 0.100 |
Why?
|
| Family Health | 1 | 2017 | 1257 | 0.100 |
Why?
|
| Antifungal Agents | 1 | 2017 | 751 | 0.100 |
Why?
|
| Boston | 2 | 2015 | 9326 | 0.100 |
Why?
|
| Organizational Culture | 1 | 2015 | 508 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 15476 | 0.090 |
Why?
|
| Inappropriate Prescribing | 1 | 2013 | 212 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 5491 | 0.090 |
Why?
|
| Unnecessary Procedures | 1 | 2013 | 415 | 0.090 |
Why?
|
| Proteomics | 1 | 2023 | 3818 | 0.090 |
Why?
|
| Adolescent | 5 | 2024 | 88196 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2023 | 23953 | 0.080 |
Why?
|
| Environmental Exposure | 1 | 2024 | 4443 | 0.080 |
Why?
|
| Allergens | 1 | 2016 | 1410 | 0.080 |
Why?
|
| Program Development | 1 | 2015 | 1297 | 0.080 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 2568 | 0.080 |
Why?
|
| Aged | 4 | 2024 | 168840 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 7996 | 0.080 |
Why?
|
| Drug Hypersensitivity | 1 | 2016 | 917 | 0.070 |
Why?
|
| Medicaid | 1 | 2021 | 2810 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 17854 | 0.070 |
Why?
|
| Neutropenia | 1 | 2012 | 884 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2015 | 2493 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2272 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 5421 | 0.070 |
Why?
|
| Obesity | 2 | 2019 | 12918 | 0.060 |
Why?
|
| Lipids | 1 | 2017 | 3342 | 0.060 |
Why?
|
| United States | 4 | 2023 | 72202 | 0.060 |
Why?
|
| Fever | 1 | 2012 | 1618 | 0.060 |
Why?
|
| Recurrence | 1 | 2017 | 8466 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2013 | 7424 | 0.060 |
Why?
|
| Time Factors | 2 | 2024 | 39947 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2013 | 6340 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 2012 | 1406 | 0.060 |
Why?
|
| Infant | 3 | 2014 | 36183 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 3685 | 0.050 |
Why?
|
| Breath Tests | 1 | 2024 | 296 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2018 | 9309 | 0.050 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2024 | 357 | 0.050 |
Why?
|
| Logistic Models | 1 | 2017 | 13240 | 0.050 |
Why?
|
| Sputum | 1 | 2024 | 506 | 0.050 |
Why?
|
| Masks | 1 | 2024 | 208 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 12653 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 15867 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2017 | 8479 | 0.050 |
Why?
|
| Young Adult | 3 | 2024 | 59068 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2013 | 5078 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 15257 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 12127 | 0.040 |
Why?
|
| Prognosis | 1 | 2017 | 29551 | 0.030 |
Why?
|
| Drug Compounding | 1 | 2017 | 246 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2017 | 712 | 0.030 |
Why?
|
| Skin Tests | 1 | 2016 | 637 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2014 | 26280 | 0.030 |
Why?
|
| Risk Factors | 2 | 2017 | 74055 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 1571 | 0.030 |
Why?
|
| Placebo Effect | 1 | 2016 | 518 | 0.030 |
Why?
|
| Immunization | 1 | 2016 | 1226 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 1438 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2016 | 4010 | 0.020 |
Why?
|
| Critical Pathways | 1 | 2012 | 474 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 3344 | 0.020 |
Why?
|
| Neoplasms | 1 | 2012 | 22083 | 0.000 |
Why?
|